LOTRONEX ACTION GROUP

www.lotronexactiongroup.org w [email protected]

 

 

March 21, 2001

 

 

Dr. Bernard Schwetz D.V.M, Ph.D.

Acting Principal Deputy Commissioner,

Food and Drug Administration

5600 Fishers Lane

Rockville, MD 20857

 

Dear Dr. Schwetz:

 

The Lotronex Action Group, an international organization representing former users of the drug alosetron (Lotronex, GlaxoSmithKline), hereby petitions the Food and Drug Administration (FDA), pursuant to the Federal Food, Drug and Cosmetic Act 21, U.S.C. Section 355(e)(3), and 21 C.F.R. 10.30, to immediately work with the manufacturer GlaxoSmithKline to permanently provide access and safe distribution of the drug to those diagnosed with diarrhea-predominant Irritable Bowel Syndrome.

 

The Lotronex Action Group believes the drug to be safe, if dispensed properly, and that the benefits of Lotronex far outweigh the potential risk for adverse side affects. [1]

 

Safety

 

We have utilized the data from a survey conducted by the Irritable Bowel Syndrome Self Help Group by former and current Lotronex users. [2]

 

The results re: side effects from taking Lotronex:

 

Constipation (123)        25%

 

Diarrhea (10)             2%

 

Ischemic Colitis (4)  1%

 

Nausea (13)               3%

 

Abdominal Discomfort - Pain (29)        6%

 

Sleep Disorder (3)     1%

 

Other (15)                   3%

 

 None (288)                59%

 

 Total Selections = 485


 

DrugVoice conducted research with over 2,000 IBS patients, many of who were former Lotronex users [3]. Research revealed a large number of users who experienced life-changing benefits from Lotronex.  Others, however either did not benefit or experienced side effects that forced them to discontinue the medication or reduce their dosage.  These results indicate that an important need for Lotronex exists, but that it is critical to monitor and target its use to the appropriate patient population.

 

Conclusions  

 

Symptoms of diarrhea-predominant IBS include urgent and explosive bowel movements, abdominal cramping, gas and nausea. Research suggests that IBS is one of the most common functional GI disorders.  But although IBS is not a life-threatening disease, it can severely diminish a person’s quality of life.

 

Members of the Lotronex Action Group, along with many other IBS sufferers, have reported a complete cessation of their IBS symptoms while taking Lotronex.  The Lotronex Action Group acknowledges that Lotronex has not helped everyone and that some who took the medication experienced side effects.  However, it is the strong belief of the Lotronex Action Group that Lotronex is safe if dispensed properly, with benefits far outweighing the potential risk for adverse side affects.

 

The FDA will have best served patients with diarrhea-predominant Irritable Syndrome by working with the manufacturer GlaxoSmithKline to permanently provide access and safe distribution of this drug.

 

ENVIRONMENTAL IMPACT STATEMENT

 

Nothing requested in this petition will have an impact on the environment.

 

CERTIFICATION

 

We certify that, to the best of our knowledge and belief, this petition includes all information and views on which this petition relies, and that it includes representative data and information known to the petitioners, which are unfavorable to the petition.


 

Yours sincerely,

 

 

 

 

Corey Miller

Coordinator

[email protected]

 

Tom R. Bell, Psy.D.

Coordinator 

[email protected]

 

Jeffrey Roberts

Coordinator

[email protected]

 

Lotronex Action Group

Email: [email protected]

URL: http://www.lotronexactiongroup.org/

 

 

 

 

 

 

[1] Supported electronic petition with 1,105 signatures at www.lotronexactiongroup.org (03/21/01)

 

[2] A non-profit Internet self help health site about Irritable Bowel Syndrome www.ibsgroup.org and www.IBSwatch.com (12/00-03/01)

 

[3] A consumer research and strategic advisory firm www.DrugVoice.com (06/00-12/00)

Hosted by www.Geocities.ws

1